Warfarin genotyping using three different platforms

American Journal of Translational Research

Volumn 2, Issue 4, 2010, Pages 441-446

  Lefferts, Joel A ^a   Schwab, Mary C ^a   Dandamudi, Uday B ^a   Lee, Hong Kee ^a   Lewis, Lionel D ^a   Tsongalis, Gregory J ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

Author keywords

CYP2C9; Genotyping methods; Invader; TaqMan PCR; Verigene; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; WARFARIN;

ANALYTICAL EQUIPMENT; ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST; FOOD AND DRUG ADMINISTRATION; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; INSTRUMENTATION; MAINTENANCE DRUG DOSE; MEDICAL STAFF; NUCLEOTIDE SEQUENCE; PATIENT CARE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TURNAROUND TIME; VKORC1 GENE; WARFARIN METABOLISM NUCLEIC ACID TEST;

EID: 77957329651     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS and ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Genetics in Medicine 2008; 10: 139-150.
2. Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR and Heit JA. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009; 84: 1079-1094.
3. Maurice CB, Barua PK, Simses D, Smith P, Howe JG and Stack G. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clinica Chimica Acta 2010; 411: 947-954.
4. Epstein RS, Moyer TP, Aubert RE, OKane DJ, Xia F, Verbrugge RR, Gage BF and Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). Journal of the American College of Cardiology 2010; 55: 2804-2812.
5. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R and Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. Human Genetics 2007; 121: 23-34.
6. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA and Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.[Erratum appears in Blood. 2009 Feb 5; 113(6): 1393-4]. Blood 2008; 112: 1013-1021.
7. Tsongalis GJ and Coleman WB. Clinical genotyping: the need for interrogation of single nucleotide polymorphisms and mutations in the clinical laboratory. Clinica Chimica Acta 2006; 363: 127-137.
8. Roper N, Storer B, Bona R and Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. Journal of Molecular Diagnostics 2010; 12: 283-291.
9. Bao YP, Huber M, Wei T-F, Marla SS, Storhoff JJ and Müller UR. SNP identification in unamplified human genomic DNA with gold nanoparticle probes. Nucl. Acids Res. 2005; 33: e15-.
10. Huber M, Wei T-F, Muller UR, Lefebvre PA, Marla SS and Bao YP. Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. Nucl. Acids Res. 2004; 32: e137-.
11. Lefferts JA, Jannetto P and Tsongalis GJ. Evaluation of the Nanosphere Verigene System and the Verigene F5/F2/MTHFR Nucleic Acid Tests. Experimental & Molecular Pathology 2009; 87: 105-108.
12. de Arruda M, Lyamichev VI, Eis PS, Iszczyszyn W, Kwiatkowski RW, Law SM, Olson MC and Rasmussen EB. Invader technology for DNA and RNA analysis: principles and applications. Expert Review of Molecular Diagnostics 2002; 2: 487-496.
13. Langley MR, Booker JK, Evans JP, McLeod HL and Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9- VKORC1 genotyping assays and warfarin-dosing algorithms. Journal of Molecular Diagnostics 2009; 11: 216-225.